[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-335335-105":59,"doc-detail-335335-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","feasibility-of-risk-assessment-for-breast-cancer-molecular-subtypes","Feasibility of risk assessment for breast cancer molecular subtypes","","Few breast cancer risk assessment models incorporate subtype-specific risk profiles. This study tested whether using tumor subtype improves discrimination by using multinomial logistic regression on 3389 women with screening mammography and later invasive breast cancer. Tumor subtype was defined by ER, PR, and HER2 expression. Discrimination was evaluated using AUC, and absolute subtype risk was derived by combining Gail BCRAT estimates with predicted subtype probabilities. Risk factor distributions differed across subtypes, highlighting distinct high-risk profiles.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/feasibility-of-risk-assessment-for-breast-cancer-molecular-subtypes/335335/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/feasibility-of-risk-assessment-for-breast-cancer-molecular-subtypes/335335.png","ImageObject",300,407,{"name":92,"@type":93},"Rowan","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What question does the study address about breast cancer risk models?","Question",{"text":112,"@type":113},"It evaluates whether a subtype-specific risk assessment approach better discriminates risk profiles across breast cancer molecular subtypes.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were tumor subtypes defined in the analysis?",{"text":117,"@type":113},"Tumor subtypes were classified by immunohistochemistry expression of estrogen receptor (ER), progesterone receptor (PR), and HER2.",{"name":119,"@type":110,"acceptedAnswer":120},"What did the study find about discrimination across subtypes?",{"text":121,"@type":113},"Discrimination differed by subtype: ER/PR−HER2+ and triple-negative breast cancer showed better AUC values than ER/PR+HER2+.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},335335,1791110123,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":39,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":46,"preview_page_count":4},1099514067415,"https://ap-avatar.wpscdn.com/avatar/100002539d78ffe74a7?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779092875211072502","Breast Cancer Research and Treatment (2024) 208:103–110  \n[https://doi.org/10.1007/s10549-024-07404-9](https://doi.org/10.1007/s10549-024-07404-9)  \nFeasibility of risk assessment for breast cancer molecular subtypes  \nAnne Marie McCarthy1 · Sarah Ehsan1 · Kevin S. Hughes2 · Constance D. Lehman3,4 · Emily F. Conant4 · Despina Kontos5 · Katrina Armstrong5 · Jinbo Chen1  \nReceived: 3 April 2024 / Accepted: 9 June 2024 / Published online: 25 June 2024 © The Author(s) 2024  \nAbstract  \nPurpose Few breast cancer risk assessment models account for the risk profiles of different tumor subtypes. This study evaluated whether a subtype-specific approach improves discrimination.  \nMethods Among 3389 women who had a screening mammogram and were later diagnosed with invasive breast cancer we performed multinomial logistic regression with tumor subtype as the outcome and known breast cancer risk factors as predictors. Tumor subtypes were defined by expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) based on immunohistochemistry. Discrimination was assessed with the area under the receiver operating curve (AUC). Absolute risk of each subtype was estimated by proportioning Gail absolute risk estimates by the predicted probabilities for each subtype. We then compared risk factor distributions for women in the highest deciles of risk for each subtype.  \nResults There were 3,073 ER/PR+ HER2 − , 340 ER/PR +HER2 + , 126 ER/PR−ER2+, and 300 triple-negative breast cancers (TNBC) . Discrimination differed by subtype; ER/PR−HER2+ (AUC: 0.64, 95% CI 0.59, 0.69) and TNBC (AUC: 0.64, 95% CI 0.61, 0.68) had better discrimination than ER/PR+HER2+ (AUC: 0.61, 95% CI 0.58, 0.64) . Compared to other subtypes, patients at high absolute risk of TNBC were younger, mostly Black, had no family history of breast cancer, and higher BMI. Those at high absolute risk of HER2+ cancers were younger and had lower BMI.  \nConclusion Our study provides proof of concept that stratifying risk prediction for breast cancer subtypes may enable identification of patients with unique profiles conferring increased risk for tumor subtypes.  \nKeywords Breast cancer · Risk assessment · Tumor subtypes · Risk prediction model · Triple-negative breast cancer  \n* Anne Marie McCarthy [annemcc@pennmedicine.upenn.edu](annemcc@pennmedicine.upenn.edu)  \n1 Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Blockley Hall, Room 833, 423 Guardian Drive, Philadelphia, PA 19104, USA  \n2 Department of Surgery, Medical University of South Carolina, Charleston, SC 29425, USA  \n3 Massachusetts General Hospital, Boston, MA, USA  \n4 Department of Radiology, Perelman School of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, USA  \n5 Columbia University Irving Medical Center, New York, NY, USA  \nIntroduction  \nDespite reductions in cancer mortality in the past several decades, breast cancer remains the second leading cause of cancer death among women in the U.S. [1] . Breast cancer has been classified into four main subtypes based on tumor molecular profiling [2] . In clinical practice, immunohistochemistry is typically used to classify tumors into subtypes defined by expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) . Tumors expressing ER and PR respond to endocrine therapies, and tumors expressing HER2 are treated with the anti-HER2 antibody drug Trastuzumab. Tumors that do not express ER, PR, or HER2, termed triple-negative breast cancers (TNBCs), do not respond to endocrine therapy or HER2-targeted therapy. TNBCs tend to be more aggressive, more likely to recur, and have higher mortality than other breast cancer subtypes [3, 4] . Breast  \ncancer subtypes also display etiologic heterogeneity, with some risk factors having different or opposite associations with TNBC versus hormone receptor-positive subtypes [5] . F","cbCaic2ggkFCkng9","https://ap.wps.com/l/cbCaic2ggkFCkng9","pdf",440595,"English","# Abstract\n## Purpose\n## Methods\n## Results\n## Conclusion\n# Introduction\n## Breast cancer subtypes and clinical implications\n## Need for subtype-specific risk profiles\n# Methods\n## Case-only design and probability estimation\n## Study population and risk factor data collection","[{\"question\":\"What question does the study address about breast cancer risk models?\",\"answer\":\"It evaluates whether a subtype-specific risk assessment approach better discriminates risk profiles across breast cancer molecular subtypes.\"},{\"question\":\"How were tumor subtypes defined in the analysis?\",\"answer\":\"Tumor subtypes were classified by immunohistochemistry expression of estrogen receptor (ER), progesterone receptor (PR), and HER2.\"},{\"question\":\"What did the study find about discrimination across subtypes?\",\"answer\":\"Discrimination differed by subtype: ER/PR−HER2+ and triple-negative breast cancer showed better AUC values than ER/PR+HER2+.\"}]","Feasibility of risk assessment for breast cancer molecular subtypes | PDF",1790010576]